2023
Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment
de Oliveira M, de Barros P, de Mathis M, Boavista R, Chacon P, Echevarria M, Ferrão Y, de Queiroz Vattimo E, Lopes A, Torres A, Diniz J, Fontenelle L, do Rosário M, Shavitt R, Miguel E, da Silva R, da Conceição Costa D. Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment. Brazilian Journal Of Psychiatry 2023, 45: 146-161. PMID: 36749887, PMCID: PMC10154009, DOI: 10.47626/1516-4446-2022-2891.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsAdult obsessive-compulsive disorderObsessive-compulsive disorderPharmacological treatmentReuptake inhibitorsEvidence-based pharmacological interventionsFirst-line pharmacological treatmentAmerican Psychiatric Association guidelinesEvidence-based pharmacological treatmentFirst-line treatmentNorepinephrine reuptake inhibitorsPrimary outcome measureSerotonin reuptake inhibitorsGlutamate-modulating agentsHigh-quality evidenceAmerican Heart AssociationLevel of evidenceTreatment of OCDBrazilian Research ConsortiumAdult patientsHeart AssociationTolerable dosesAssociation guidelinesTreatment recommendationsPharmacological interventionsBrazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part II: cognitive-behavioral therapy
de Mathis M, Chacon P, Boavista R, de Oliveira M, de Barros P, Echevarria M, Ferrão Y, de Queiroz Vattimo E, Lopes A, Torres A, Diniz J, Fontenelle L, do Rosário M, Shavitt R, da Silva R, Miguel E, da Conceição Costa D. Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part II: cognitive-behavioral therapy. Brazilian Journal Of Psychiatry 2023, 45: 431-447. PMID: 37718254, PMCID: PMC10894635, DOI: 10.47626/1516-4446-2023-3081.Peer-Reviewed Original ResearchAdult obsessive-compulsive disorderObsessive-compulsive disorderTherapy treatmentHigh-quality scientific evidenceTreatment of adultsPrimary outcome measureHigh-quality evidenceAmerican Heart AssociationLevel of evidenceInternet-delivered CBTCognitive behavioral therapy treatmentBrazilian Research ConsortiumAdult patientsHeart AssociationClinical guidelinesTreatment recommendationsOutcome measuresAmerican CollegeSystematic reviewCBT interventionClinical interventionsCBT treatmentStudy designCBT protocolResponse prevention
2018
Assessment of Safety and Outcome of Lateral Hypothalamic Deep Brain Stimulation for Obesity in a Small Series of Patients With Prader-Willi Syndrome
Franco R, Fonoff E, Alvarenga P, Alho E, Lopes A, Hoexter M, Batistuzzo M, Paiva R, Taub A, Shavitt R, Miguel E, Teixeira M, Damiani D, Hamani C. Assessment of Safety and Outcome of Lateral Hypothalamic Deep Brain Stimulation for Obesity in a Small Series of Patients With Prader-Willi Syndrome. JAMA Network Open 2018, 1: e185275. PMID: 30646396, PMCID: PMC6324383, DOI: 10.1001/jamanetworkopen.2018.5275.Peer-Reviewed Original ResearchConceptsDeep brain stimulationPrader-Willi syndromeBody mass indexBlood workupMass indexSleep studiesHormonal levelsBrain stimulationBaseline mean body mass indexLow-frequency deep brain stimulationOutcome of DBSHigh-frequency deep brain stimulationLong-term deep brain stimulationHypothalamic deep brain stimulationLong-term DBS treatmentMean body mass indexSimilar psychiatric conditionsPrevious bariatric surgeryMonths of treatmentPrimary outcome measureUse of medicationsLateral hypothalamic areaHospital das ClínicasDeep brain stimulation electrodesAssessment of safety
2017
Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, Miguel EC, Shavitt RG. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder. The Journal Of Clinical Psychiatry 2017, 78: e766-e773. PMID: 28617566, DOI: 10.4088/jcp.16m11101.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcysteineAdolescentAdultAgedAnxiety DisordersComorbidityDepressive DisorderDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationFemaleHumansMaleMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesPsychometricsSelective Serotonin Reuptake InhibitorsYoung AdultConceptsTreatment-resistant obsessive-compulsive disorderObsessive-compulsive disorderY-BOCS scoresN-acetylcysteineNAC groupYale-Brown Obsessive Compulsive Scale scoresTreatment-resistant OCD patientsBaseline Y-BOCS scoresTreatment-Resistant ObsessivePrimary outcome measureAnxiety symptomsDSM-IV criteriaSymptom dimensionsCompulsive Scale scoresSpecific OCD symptom dimensionsOCD symptom dimensionsAntioxidant medicationsAbdominal painPlacebo groupGlutamate modulatorsSecondary outcomesTertiary hospitalOutpatient clinicSeverity scoreWeek 16